In Vitro Activity of New β-Lactam–β-Lactamase Inhibitor Combinations and Comparators against Clinical Isolates of Gram-Negative Bacilli: Results from the China Antimicrobial Surveillance Network (CHINET) in 2019

In Vitro Activity of New β-Lactam–β-Lactamase Inhibitor Combinations and Comparators against Clinical Isolates of Gram-Negative Bacilli: Results from the China Antimicrobial Surveillance Network (CHINET) in 2019

ABSTRACT Novel β-lactam–β-lactamase inhibitor combinations (BLBLIs) are in clinical development for the treatment of infections caused by carbapenem-resistant and difficult-to-treat resistant (DTR) (defined as resistance to all tested β-lactams and fluoroquinolones) Gram-negative bacilli. This study...

Full description

Bibliographic Details
Main Authors: Yan Guo, Renru Han, Bo Jiang, Li Ding, Fengzhen Yang, Beijia Zheng, Yang Yang, Shi Wu, Dandan Yin, Demei Zhu, Fupin Hu
Format: Article
Language:English
Published: American Society for Microbiology 2022-08-01
Series:Microbiology Spectrum
Subjects:
β-lactam–β-lactamase inhibitor combinations
difficult-to-treat resistance
cefepime-zidebactam
ceftazidime-avibactam
carbapenemase
Online Access:https://journals.asm.org/doi/10.1128/spectrum.01854-22

Internet

https://journals.asm.org/doi/10.1128/spectrum.01854-22

Similar Items